20 results about "Degenerative disc disease" patented technology

Compositions and methods for treating degenerative disc disease in a subject in need thereof are provided. Specifically, the methods include locally administering a therapeutically effective amount of one or more matrix-modifying enzymes to a cartilage endplate to increase the permeability of the cartilage endplate and improve disc nutrient transport.

This invention provides a genetically engineered biomimetic microsphere for hydration remodeling, its preparation method, and its application, belonging to the field of biomedical technology. This invention develops an injectable composite system, GBA / SRGN@HADA@GelMA, which possesses the ability to regulate hydration and intervene in genes through interface biomimetic design and multi-level functional integration. It uses HADA as a moisturizing outer layer, provides mechanical support through GelMA microspheres, and achieves targeted delivery of SRGN siRNA through G5-GBA loading, thereby achieving synergistic regulation of the degenerative nucleus pulposus microenvironment. GBA / SRGN@HADA@GelMA reduces the expression of inflammatory factors and matrix degradation genes, and significantly promotes the accumulation of HA and lubricating proteins. This enhances the water retention capacity and interfacial lubrication of the nucleus pulposus, thereby improving compressive elasticity and energy absorption capacity. This invention is the first to combine continuous water regulation, lubrication, mechanical buffering, and extracellular matrix homeostasis regulation to synergistically delay intervertebral disc degeneration, providing an excellent treatment strategy for degenerative intervertebral disc diseases.

Methods and compositions relating to the treatment of degenerative disc disease are provided.SOLUTION: In some embodiments, cannabidiol is utilized to enhance the therapeutic and / or regenerative activity of fibroblasts. In other embodiments, cannabidiol is utilized to augment the reparative effects of other regenerative cells, including monocytes, mesenchymal stem cells, and / or hematopoietic stem cells. In some embodiments, cannabidiol is utilized in the culture media of regenerative cells prior to administration of said cells.SELECTED DRAWING: Figure 1

The invention relates to an artificial disc prosthesis particularly suitable for use in the treatment of cervical degenerative disc disease, capable of mimicking all forward, backward, right and left movements in the sagittal or longitudinal, horizontal or axial or transverse planes, coronal or frontal planes and providing sufficient mechanical support for this.

Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.

Disclosed herein are compositions and methods for treatment and prevention of low back pain. The compositions include vectors comprising nucleotide sequences encoding one or more CRISPR-Cas system guide RNAs and a RNA-directed nuclease. The methods include modulating expression of one or more genes in a cell using the compositions, introducing a CRISPR-Cas system into a cell comprising one or more vectors comprising the compositions, including site-specific DNA cleavage in a cell, and treating a subject having lower back pain, and lower back pain caused by degenerative disc disease using the compositions disclosed herein.

A spinal disc implant including a body defined by a plurality of interwoven or braided nitinol strands. The body includes a first end and a second end. The nitinol strands come together at the first end and are secured with a first fitting. The nitinol strands also come together at the second end and are secured with a second fitting. The second fitting can include a snare hook. The braided nitinol skeleton is internally assembled within the intervertebral disc. The implant is filled with liquid, gel or silicone when utilized as a motion preserving nucleus pulpous implant. The implant is filled with bone graft material when utilized as an inter-body fusion implant. An instrument and technique that provides a minimally invasive “needle based” solution to address degenerative disc disease with enhanced structural integrity of the spine compared to conventional surgical devices and techniques.

A power tool for removing an intervertebral disc and preparing vertebral endplates is described. The power tool may include a cutting element, and the height of the cutting element may be adjustable. The cutting element may be a braided cable and may include one or more beads to enhance the effectiveness of the cable. The cutting element may have a minimum height requirement, which may not be satisfied in patients with a collapsed disc due to degenerative disc disorder. For these patients, also described are bone tamps for increasing the intervertebral distance and providing access to tissues distal to the tamp. One type of bone tamp features an inflatable balloon with an inner lumen. Another type of bone tamp includes an expanding distal end and an inner cannula. Also described is a manual expander scraper tool that is compatible with both types of bone tamp.

Described herein are compositions and methods for treatment and prevention of low back pain. The compositions include vectors comprising nucleotide sequences encoding one or more CRISPR-Cas system guide RNAs and a RNA-directed nuclease. The methods include modulating expression of one or more genes in a cell using said compositions, introducing a CRISPR-Cas system into a cell comprising one or more vectors comprising said compositions, inducing site-specific DNA cleavage in a cell, and treating a subject having lower back pain, and lower back pain caused by degenerative disc disease using the compositions disclosed herein.

Compositions of matter, interventions and protocols for treatment of degenerative disc disease through administration of B regulatory cells and / or stimulation of B regulatory cell generation. B regulatory cells can be administered intradiscally in order to support regenerative processes of endogenous nucleus pulposus cells or administered regenerative cells. Peri-spinal administration of B regulatory cells can alter the microenvironment to support activity of therapeutic cells capable of increasing extracellular matrix quality and quantity. B regulatory cells can be expanded in vitro from progenitor cells including induced pluripotent stem cells, or may be utilized from adult progenitor sources such as peripheral blood, cord blood, and bone marrow.

A spinal disc implant including a body defined by a plurality of interwoven or braided nitinol strands. The body includes a first end and a second end. The nitinol strands come together at the first end and are secured with a first fitting. The nitinol strands also come together at the second end and are secured with a second fitting. The second fitting can include a snare hook. The braided nitinol skeleton is internally assembled within the intervertebral disc. The implant is filled with liquid, gel or silicone when utilized as a motion preserving nucleus pulpous implant. The implant is filled with bone graft material when utilized as an inter-body fusion implant. An instrument and technique that provides a minimally invasive “needle based” solution to address degenerative disc disease with enhanced structural integrity of the spine compared to conventional surgical devices and techniques.

The invention relates to an artificial intervertebral disc prosthesis that can mimic all movements in the sagittal or longitudinal, horizontal or axial or transverse plane, in coronal or frontal planes, forwards, backwards, right and left, and provides sufficient mechanical support for this, in particular for use in the treatment of cervical degenerative disc disease.

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

The present disclosure relates to potency assays for cell therapy products. To provide a potency assay of a cell population comprising mesenchymal progenitor or stem cells.SOLUTION: The present invention relates to a method of measuring the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor or stem cells based on the levels of TGF-9 they release during culture. The invention also relates to an isolated population of mesenchymal lineage precursor or stem cells selected on the basis of the level of TGF-9 levels that the cells release in culture. The invention further relates to treating a subject suffering from degenerative disc disease by administering a cell population so selected.SELECTED DRAWING: None

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

Methods and compositions related to promoting intervertebral disc regeneration and / or repair in an individual are provided.SOLUTION: In some cases, conditioned media is obtained from fibroblasts stimulated with one or more opioid receptor antagonists and one or more toll-like receptor agonists. Conditioned medium from fibroblasts may be provided in an effective amount to an individual in need thereof.SELECTED DRAWING: Figure 1

Disclosed are means and compositions of matter for treating degenerative disc disease and associated pain in part by stimulating enhanced local perfusion and reduction of inflammation. In one embodiment administration of inducible pluripotent stem cell derived mesenchymal stem cells is performed wherein said cells are optimized for migration and / or retention into perispinal environment. In some embodiments said mesenchymal stem cells are optimized for enhanced angiogenesis and / or suppression of inflammation. In another embodiment inducible pluripotent stem cell derived T regulatory cells are administered alone or with said mesenchymal stem cells in order to elicit enhanced perispinal perfusion while concurrently reducing inflammation.

The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells the based on their released TGF-ϑ levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-ϑ levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.